A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.
Biopharmaceutical company Ocugen has announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, which is a whole virion inactivated Covid vaccine candidate.
Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.
Belgium-based biopharmaceutical firm UCB has expanded its collaboration with technology company Microsoft to accelerate discovery and development of drugs for people living with severe diseases in immunology and neurology.
GlaxoSmithKline has signed a €150m collaboration agreement with German global pharmaceutical company CureVac in a bid to jointly develop next-generation mRNA vaccines for Covid-19.
A new study claims palbociclib, an approved breast cancer drug, can treat an aggressive form of the cancer, bringing hope to thousands of afflicted women in the UK.
American pharma giant Merck has announced that it has discontinued the development of its SARS-CoV-2/Covid-19 vaccine candidates V590 and V591, after they performed poorly in phase 1 clinical trials.
Pfizer and BioNTech have revealed results of an in vitro study that offers additional data on the capability of sera obtained from people who were immunised with their Covid-19 vaccine, BNT162b2, to neutralise the B.1.1.7 lineage (VOC 202012/01).
Gritstone Oncology, a biotech firm developing vaccines, has announced that it is advancing the development of a second generation vaccine against Covid-19.
KSQ Therapeutics has joined forces with Japan-based Takeda Pharmaceutical to research, develop, and commercialise novel immuno-oncology therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.